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Objective: The aim of this study was to investigate the
effect of pre-treatment verification imaging with mega-
voltage X-rays on cancer and normal cell survival in vitro
and to compare the findings with theoretically modelled
data. Since the dose received from pre-treatment imag-
ing can be significant, the incorporation of this dose at
the planning stage of treatment has been suggested.
Methods: The impact of imaging dose incorporation on
cell survival was investigated by clonogenic assay of
irradiated DU-145 prostate cancer, H460 non-small-cell
lung cancer and AGO-1522b normal tissue fibroblast cells.
Clinically relevant imaging-to-treatment times of 7.5 and
15min were chosen for this study. The theoretical magni-
tude of the loss of radiobiological efficacy due to sublethal
damage repair was investigated using the Lea–Catcheside
dose protraction factor model.
Results: For the cell lines investigated, the experimental
data showed that imaging dose incorporation had no
significant impact on cell survival. These findings were in
close agreement with theoretical results.
Conclusion: For the conditions investigated, the results
suggest that allowance for the imaging dose at the
planning stage of treatment should not adversely affect
treatment efficacy.
Advances in knowledge: There is a paucity of data in the
literature on imaging effects in radiotherapy. This article
presents a systematic study of imaging dose effects on
cancer and normal cell survival, providing both theoret-
ical and experimental evidence for clinically relevant
imaging doses and imaging-to-treatment times. The data
provide a firm foundation for further study into this highly
relevant area of research.
Radiotherapy is in a period of rapid scientiﬁc and clinical
development. With the introduction of adaptive radio-
therapy1 and the increasing use of high-precision techni-
ques,2 there has been an increased requirement for
veriﬁcation imaging. Veriﬁcation imaging can be carried
out using megavoltage portal beams, kilovoltage planar
ﬁelds or cone beam CT (CBCT) using kilovoltage or
megavoltage beams. Dependent on the imaging technique
employed, the dose required to acquire an image of ade-
quate quality can vary signiﬁcantly. Whilst doses ranging
from a few centigrays to 10 cGy are required for mega-
voltage portal imaging and CBCT, doses in the order of
megagrays are typically required to obtain an image of
adequate quality using kilovoltage planar imaging.3 The
choice of imaging modality is dictated by the available
technology, with megavoltage portal imaging being the
most established imaging option. However, with the ad-
dition of on-board kilovoltage imaging systems, kilovoltage
imaging options are becoming much more widespread
both for their improved image contrast and reduced
patient dose.4
Associated with this increasing imaging dose burden are
concerns regarding the increased risk of deterministic and
stochastic effects due to increased radiation exposure.3,5–7
Whilst it is important to quantitatively determine the long-
term effects of increased concomitant exposures, it is
equally important to determine any potential changes to
the effectiveness of the therapeutic dose.5,8–10
Low-dose biological phenomena such as adaptive
responses11–13 and bystander signalling14–17 hold the po-
tential to signiﬁcantly alter the response of cells to radiation
and thus treatment efﬁcacy. However, since these effects
tend to occur over a period of hours, it is unlikely that they
will have any signiﬁcant impact with regard to imaging in the
treatment room.18 By contrast, sublethal damage repair that can
occur over a period of minutes may be of signiﬁcance in radio-
therapy when the dose delivered from imaging beams is in-
corporated with the prescribed therapeutic dose at the treatment
planning stage.9,10,19–22
The effect of imaging dose incorporation was previously
reported in a preliminary study by Yang et al.10 In particular,
they showed an unexpected 12.6% increase in cell survival when
H460 cells were exposed to a pre-treatment imaging dose of
5 cGy followed by a therapeutic dose of 200 cGy, they attributed
Table 1. Average imaging-to-treatment times (tI–T) and overall treatment times (OTT) determined from a clinical audit of 30 prostate
and pelvic node intensity-modulated radiotherapy (IMRT) patients and 30 prostate three-dimensional conformal radiotherapy
(3DCRT) patients
Treatment type tI–T6 SD (min) Upper 95% CI (tI–T) OTT6 SD (min) Upper 95% CI (OTT)
IMRT 8.566 3.62 15.67 14.936 4.4 23.55
3DCRT 8.186 5.25 18.48 11.486 5.62 22.48
CI, confidence interval; SD, standard deviation associated with the calculated values.
Figure 1. (a) An image of the irradiation set-up. (b) A schematic representation of the experimental set-up. The cells were irradiated
at 4.8 cm deep in a custom-made polymethyl methacrylate phantom, with 5cm of backscatter. (Inset) the dose profile across the
three flasks at the cell level, acquired using a two-dimensional matrix ion chamber array at an effective depth of 5cm.
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their ﬁndings to increased cell proliferation. The results suggest
that the delivery of a fraction of the therapeutic dose by imaging
beams presents a potential issue since the time from imaging to
delivery of the treatment can be of the order of 5–20min, having
a negative impact on treatment efﬁcacy owing to low-dose bi-
ological phenomena16 or sublethal damage repair that may be
initiated during this time.9,19 Although the need for imaging
dose incorporation is justiﬁed, the potential to affect treatment
efﬁcacy should be determined.
To investigate the radiobiological impact of imaging dose in-
corporation, a series of experiments were conducted in vitro,
where the imaging doses were incorporated with the prescribed
treatment dose for different human cell lines. As megavoltage
portal imaging is the most widely used type of imaging for
veriﬁcation and as it delivers a higher dose, the study was carried
out using 6MV beams for both the imaging and treatment
components. The theoretical magnitude of this effect and its
impact on cell survival was quantiﬁed using radiobiological
modelling based on the Lea–Catcheside dose protraction factor23
as a comparison to the experimental data.
METHODS AND MATERIALS
Clinical audit
Using the Varian ofﬂine review program (Varian Medical Sys-
tems, Inc., Palo Alto, CA), an analysis of the time taken between
the acquisition of a pre-treatment veriﬁcation image and the
treatment delivery was carried out for 30 patients for prostate
and pelvic node intensity-modulated radiotherapy (IMRT) and
30 prostate patients for three-dimensional conformal radio-
therapy (3DCRT), who were undergoing treatment at the
Northern Ireland Cancer Centre (Belfast, UK). The time be-
tween the acquisition of the ﬁrst megavoltage portal image and
treatment was recorded (tI–T), as was the overall treatment time
(the average time from the acquisition of the ﬁrst megavoltage
portal image to the end of the treatment). The results are pre-
sented in Table 1. For the IMRT and 3DCRT patient groups,
a total of 106 and 101 treatment fractions were analysed, re-
spectively. From these data, image-to-treatment times (tI–T) of
7.5 and 15min were chosen for this study, as they were con-
sidered to be broadly representative of the average and upper
extreme values of this data set. These values are consistent with
typical imaging-to-treatment times of 5–20min that have been
reported previously.9
Cell culture
Experiments were conducted using the human prostate cancer
cell line DU-145 and the human non-small-cell lung cancer cell
line H460, obtained from the American Type Culture Collection
LGC Standards (Teddington, UK). Both cancer cell lines were
grown in RPMI-1640 with L-glutamine (Lonza, Cambridge, UK),
supplemented with 10% foetal bovine serum and 1% penicillin/
streptomycin (Gibco®, Paisley, UK). The human tissue ﬁbroblast
cell line (AG0-1522b) cells were purchased from the Coriell
Figure 2. A schematic representation of the experimental design. The standard group received the prescribed dose (DT) in a single
irradiation, delivered at 400MUmin21 ( _DT); while the split-dose group received the prescribed dose in two time-separated irradiations
—5cGy (DI) at a dose rate of 100MUmin
21 ( _DI) followed by the remainder of the total dose prescribed at a dose rate of 400MUmin
21.
Time between delivery of the pre-treatment imaging dose and the remainder of the total dose prescribed (tI–T) was either 7.5 or 15min.
4tI, time taken to deliver the imaging beam; 4tT, time taken to deliver the treatment beam; tstart, start time; tstop, stop time.
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Institute forMedical Research (Camden, NJ) and grown in Eagle’s
minimum essential medium with deoxyribonucleosides and deox-
yribonucleotides (Lonza), supplemented with 20% foetal bovine
serum and 1%penicillin/streptomycin. All cell lines weremaintained
at 37 °C in an atmosphere of 5% CO2 in air and 95% humidity.
Clonogenic assay
The effect of radiation on cell viability was investigated using the
clonogenic assay.24 All cells were plated 18–24 h prior to expo-
sure. The DU-145 and H460 cells received doses of 2, 4 or 8 Gy,
whereas the more radiosensitive AGO-1522b cells received doses
of 1, 2 or 4Gy. Prior to irradiation, the culture ﬂasks were com-
pletely ﬁlled with RPMI-1640 incomplete media to ensure full
scatter conditions. Irradiations were conducted at room tempera-
ture (2562 °C). All exposures were conducted in triplicate on at
least three independent occasions. For all experiments, six un-
exposed controls were prepared and sham irradiated. After expo-
sure, the incomplete media was removed from the ﬂasks and
replaced with 5ml of RPMI-1640 complete media. The cells were
subsequently incubated for 8–12 days at 37 °C, in an atmosphere of
5%CO2 in air and 95% humidity. At the appropriate time, the cells
were stained with 0.5% crystal violet in 50% methanol. Cell colo-
nies were scored manually using the 50-cell exclusion criterion.
Irradiation set-up and in vivo experimental design
A monolayer of cells was irradiated in T25 culture ﬂasks with
6MV X-rays produced by a TrueBeam™ LINAC (Varian Medical
Systems, Inc.) under a uniform beam (Figure 1a). Three T25 ﬂasks
were irradiated simultaneously. The cells were separated by a dis-
tance of 100 cm from the X-ray source, for a ﬁeld size of
203 20 cm (at 100 cm). A schematic representation of the
experimental set-up is shown in Figure 1b.
Investigations were conducted to determine the effect of com-
bining a pre-treatment imaging dose of 5 cGy25 with a variable
therapeutic dose to deliver total doses of 2, 4 or 8Gy for DU-145
andH460 cells or 1, 2 or 4Gy for the AGO-1552b cells. The delivery
of the two parts of the total dose was separated by times of 7.5 or
15min. Standard dose–response curves of cell survival were also
generated for each data set as a comparison. Figure 2 shows
a schematic representation of the two irradiation groups—standard
and split dose. The standard group received the prescribed dose
(DT) in a single irradiation, delivered at 400 monitor units (MU)
min21; whereas, the split-dose group received the prescribed dose
in two time-delayed irradiations. Speciﬁcally, the ﬁrst irradia-
tion delivered a dose of 5 cGy at 100MUmin21 to the cells
(representing a pre-treatment imaging dose) and the second
irradiation delivered the remainder of the total dose prescribed,
at a dose rate of 400MUmin21.
Dosimetric verification
Dosimetry measurements were performed using a Farmer®
ionization chamber (NE-Technology Ltd, Reading, UK) at a ra-
diological equivalent depth to the cell position with a calibration
traceable to the National Physical Laboratory, in accordance with
the Institute of Physical Sciences in Medicine 1990 code of
practice.26 As a further veriﬁcation of the ionization chamber
measurements, a series of CT images of the polymethyl
methacrylate phantom containing the culture ﬂasks were
taken with a GE LightSpeed® CT scanner (GE Healthcare,
Chalfont St Giles, UK). The CT data set was sent from the CT
scanner to the Eclipse™ (Varian Medical Systems, Inc.)
treatment planning system where the prescription point was
positioned at the cell level, at the centre of the middle ﬂask
and a 6MV 203 20 cm2 ﬁeld planned to deliver a prescription
dose of 2 Gy. The number of monitor units required to deliver
the prescribed dose was found to be in agreement with the
dose determined using the ionization chamber reading to
within 61%. The dose variation between the three ﬂasks ir-
radiated at the same time was ,1%.
Experimental data analyses
The fraction of cells surviving after treatment was calculated as
the ratio of the number of colonies in the exposed ﬂask to the
number of cells seeded, corrected for the plating efﬁciency of the
sham-irradiated controls. The standard error associated with
each data point was calculated. The data were subsequently
plotted using Origin Pro v. 8 (Origin Lab, Northampton, MA)
and ﬁtted to the linear quadratic equation for single acute doses:
surviving fraction5e2 ðaD1bD
2Þ; where D is the total dose and a
and b are tissue-speciﬁc parameters. The ﬁts were weighted by
1/(variance of each data point). F-tests were carried out to de-
termine if any differences in the ﬁts to the data sets were
Table 2. Parameter definition and values used to determine the dose protraction factor fG½ _DI and TðtÞg
Symbol Definition DU-145 H460 AGO-1522b
DtI Imaging time – – –
DtT Treatment time – – –
DT Total dose (Gy) 2, 4 or 8 2, 4 or 8 1, 2 or 4
DI Imaging dose (Gy) 0.05 0.05 0.05
_DT Therapeutic dose rate (Gy min
21) 4 4 4
D
_
I Imaging dose rate (Gy min
21) 1 1 1
R1=2 Repair half-time (min) 16 90 130
tI–T Imaging-to-treatment time (min) 7.5 or 15 7.5 or 15 7.5 or 15
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statistically signiﬁcant. Statistical signiﬁcance was assumed for
p, 0.05.
Modelling the dose protraction
The effectiveness of a prescribed dose of radiation was calcu-
lated9 when it was part delivered by a 6MV imaging beam
(100MUmin21), either 7.5 or 15min prior to delivery of the re-
mainder of the prescribed dose by a 6MV treatment beam
(400MUmin21). By integration of the Lea–Catcheside dose pro-
traction factor fG½ _DðtÞg,23 which is based on an assumed mono-
exponential pattern of sublethal damage recovery and takes account
of the imaging and treatment doses, the protracted exposure time
and the time gap between imaging and treatment delivery, the
following Equation (1) is obtained:
G

_DI and TðtÞ

5
1
_DIDtI1
_DTDtT
2

_DIDtI
2
gðmDtIÞ
1
2 _DI
_DT
m2
e2mtI2T

12 e2mDtI

12 e2mDtT

1

_DTDtT
2
gðmDtTÞ

(1)
Wherem5lnð2Þ=R1=2 and ðmDtpÞ52mDtp1 e2mDtp 2 1=ðmDtpÞ2;
where Dtp is the duration of the exposure. The deﬁnitions of the
individual parameters contained within this equation are pre-
sented in Table 2. Using the experimentally determined a and b
values for each cell line, the calculated dose protraction factor
(G) was subsequently incorporated into the linear quadratic
model [Surviving fraction5e2 ðaD1GbD
2Þ] to calculate cell sur-
vival. From the modelled data of cell survival, an effective dose
was then calculated to determine the dose required to achieve
the same level of cell kill if the dose was delivered in a single
fraction.
RESULTS
Experimental data
Figure 3 shows the survival curves generated for DU-145,
H460 and AGO-1552b cells for the standard-dose, split-dose
(tI–T) 5 7.5min and split-dose tI–T5 15min cases. The de-
termined a and b values for each cell line for each combi-
nation of irradiation conditions are presented in Table 3.
Analysis did not show any statistically signiﬁcant differences
between the control curve vs the 7.5-min split-dose curve for
each cell line (DU-145, p5 0.53; H460, p5 0.32; AGO-1552b,
p5 0.35) or the control curve vs the 15-min split-dose curve
(DU-145, p5 0.39; H460, p5 0.27, AGO-1552b, p5 0.37).
Moreover, no signiﬁcant differences were found between the 7.5-
and 15-min split dose curves (DU-145, p5 0.58; H460, p5 0.28;
AGO-1552b, p5 0.36).
Theoretical data
The dose protraction factors fG½ _DI and TðtÞg were calculated for
each dose and each imaging-to-treatment times investigated for
the DU-145, H460 and AGO-1552b cells. The parameter values
used to calculate G½ _DI and TðtÞ are presented in Table 2. Taken
from the literature, repair half-times of 16, 90 and 130min were
used for DU-145, H460 and AGO-1552b cells, respectively.21,27,28
The calculated values were incorporated into the linear quadratic
model to calculate the corresponding surviving fractions. The
Figure 3. Cell survival curves following exposure to 6MV beams
delivered either as a standard treatment at 400MUmin21 (circles)
or as a split-dose (5cGy imaging dose at 100MUmin21 and
treatment dose at 400MUmin21) with imaging-to-treatment
times57.5 (triangles) or 15min (squares) for (a) DU-145, (b)
H460 and (c) AGO-1522b cells. The error bars on the data
points represent6 standard error of the mean. Only fits to the
standard treatment data are plotted for each cell line.
Full paper: Radiobiological consequences of pre-treatment verification imaging BJR
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instant effect was also calculated using the formula:
surviving fraction5e2 ðaD1bD
2Þ for each dose, i.e. the effect when
the dose was delivered in a single irradiation by the treatment beam
(400MUmin21). As a comparison, the generated surviving fraction
data for the split-dose treatments were used to calculate the pro-
tracted effective dose for each dose point, i.e. the dose required to
cause the same level of cell kill if the dose was delivered in a single
fraction.
The calculated surviving fractions for imaging-to-treatment times
of 7.5 and 15min for DU-145, H460 and AGO-1552b cells are
presented in Table 4. The data were subsequently plotted and ﬁtted
using the linear quadratic model, although data were not presented
as overlaid curves. The theoretical results are in good agreement
with the experimental data presented previously. Currently, dose
incorporation is rarely implemented owing to the practical difﬁ-
culties of calculating imaging dose and summing this with the
treatment dose, as well as the uncertainty of repeat exposures during
treatment to ensure set-up accuracy. Hence, the modelling was used
to determine the effect of not incorporating the dose into the plan.
Table 5 shows that the protracted effective dose was lower only than
the prescribed instant effect for the DU-145 cells delivering 8Gy.
DISCUSSION
In the era of high-precision conformal and adaptive radio-
therapy, the use of imaging in the treatment room is set to
increase. Since the dose received from pre-treatment veriﬁca-
tion imaging can be considerable,3,8 it has been suggested that
this dose should be accounted for at the treatment planning
stage.3,29,30 Although this allows for the correct calculation of
normal tissue and tumour dose, imaging dose incorporation
has the potential to impact the treatment efﬁcacy in an adverse
manner. This is because in the time between pre-treatment
imaging and delivery of the remaining treatment dose, sub-
lethal damage repair may occur,31 which may lead to a reduced
amount of sublethal damage that can be subsequently com-
pounded to lethal damage by the treatment dose. In turn, this
has the potential to result in an increase in the surviving
fraction of cells after treatment.
The aim of this research was to investigate the impact of imaging
dose incorporation on cell survival in vitro, in both human
cancer and normal tissue cell lines. The results from the ex-
perimental studies presented here reveal that imaging dose in-
corporation has no signiﬁcant impact on cell survival, for
clinically relevant imaging-to-treatment times of 7.5 or 15min
for all cell lines investigated. Results from DU-145 cells support
the results from related studies by Butterworth et al32 and
McGarry et al,33 who reported no statistically signiﬁcant trends
towards increased cell survival in DU-145 cells for prolonged
treatment delivery times. AGO-1522b cells have shown some
dose rate effects for non-modulated beams,33 but no effects were
observed in this study. The results for H460 cells are in clear
disagreement with the preliminary experimental ﬁndings of
Yang et al10 who reported a 12.6% (p, 0.02) increase in cell
survival when a 5-cGy pre-treatment imaging dose was delivered
to the cells prior to the delivery of a therapeutic dose of 200 cGy.
However, the details of the experimental protocol used and
speciﬁc results of this study by Yang et al10 remain unpublished.
Bewes et al34 investigated the impact of prolonged treatment
delivery times on cell survival. They reported that as the time
taken to deliver a speciﬁed dose of radiation increased, a corre-
sponding increase in cell survival was observed for a melanoma
cell line (MM576) and for H460 cells. The study by Bewes et al34
highlights that extended treatment times may signiﬁcantly im-
pact tumour control in an adverse manner; however, these
experiments were undertaken for continuous dose irradiation,
whereas the study reported herein is for a split-dose irradiation
scenario.
The experimental data presented for AGO-1522b, DU-145 and
H460 cells were found to be in excellent agreement with the
theoretically determined data, which was modelled using the
Lea–Catcheside dose protraction factor.9,23 These results are
encouraging, as the imaging-to-treatment times used are of
clinical relevance. Furthermore, in terms of effective dose (i.e.
the dose required to achieve the same level of cell kill if the dose
was delivered in a single irradiation), the largest percentage
difference was found to be 1.37%. From both the experimental
and theoretical data presented here, incorporation of an im-
aging dose of 5 cGy with a prescribed treatment dose, for
imaging-to-treatment times not exceeding 15min, would not
be expected to impact tumour control in an adverse manner
since no signiﬁcant change in cell survival is observed. These
ﬁndings are in agreement with the theoretical study of Flynn9
who reported that the loss of radiobiological efﬁciency due to
sublethal damage repair, when imaging doses are incorporated
with the treatment dose, is clinically insigniﬁcant if the imaging
dose delivered is #5% of the total dose, or if the delay time
between imaging and treatment is in the order of 5min.
Although sublethal damage repair is a key player in the context
of the research presented here, other biological effects such as
adaptive responses and bystander effects may become more in-
ﬂuential as radiotherapy techniques and delivery options become
more sophisticated.17
Table 3. Calculated a and b values for the three cell lines investigated
Experimental group
DU-145 H460 AGO-1552b
a b a b a b
Control 0.086 0.04 0.026 0.01 0.2566 0.06 0.036 0.01 0.686 0.04 0.006 0.01
7.5min 0.036 0.03 0.036 0.01 0.2736 0.05 0.036 0.01 0.756 0.05 0.006 0.01
15min 0.086 0.04 0.026 0.01 0.2486 0.05 0.036 0.01 0.686 0.04 0.006 0.01
Data presented as mean 6 standard deviation.
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Extrapolation of these in vitro and theoretical ﬁndings to the
clinical context is restricted owing to the limitations of two-
dimensional cell culture methods, which do not replicate the
vascular architecture of complex tumours. In addition, the fact
that only megavoltage imaging beams were used in this study
may limit the applicability of the results to other types of ver-
iﬁcation imaging. However, the preliminary megavoltage dose
represents a portal imaging dose, which is on the higher side of
the doses received by image-guided radiotherapy. Delivering
CBCTor even paired images from different directions will result
in non-homogenous (non-uniform) doses across organs or
cells.3 This could be complicated further by differences in dose
deposition from kilovoltage imaging compared with megavoltage
imaging and other factors such as patient dimensions and the
treatment site. Although all of these factors cannot be taken into
account, it is important to study the effects with a known uni-
form dose, delivered in a controlled fashion, before further in-
vestigation into this complex area of radiotherapy. With such
a paucity of data in the literature on imaging effects, the novel
work presented here provides a framework for further study.
CONCLUSIONS
For DU-145, H460 and AGO-1522b cells, incorporation of an
imaging dose of 5 cGy with the prescribed treatment dose was
not found to have a signiﬁcant impact on cell survival, for
clinically relevant imaging-to-treatment times of 7.5 or 15min.
These ﬁndings were in good agreement with theoretically mod-
elled data, based on the Lea–Catcheside dose protraction factor.
These data suggest that imaging dose incorporation should not
be expected to impact on tumour control in an adverse manner,
since no signiﬁcant increase in cell survival was observed.
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